Combined mesenchymal stem cell transplantation and interleukin-1 receptor antagonism after partial hepatectomy

World J Gastroenterol. 2016 Apr 28;22(16):4120-35. doi: 10.3748/wjg.v22.i16.4120.

Abstract

Aim: To study the therapeutic effects of mesenchymal stem cells (MSCs) and an interleukin-1 receptor antagonist (IL-1Ra) in acute liver failure.

Methods: Chinese experimental miniature swine (15 ± 3 kg, 5-8 mo) were obtained from the Laboratory Animal Centre of the Affiliated Drum Tower Hospital of Nanjing University Medical School. Acute liver failure was induced via 85% hepatectomy, and animals were treated by MSC transplantation combined with IL-1Ra injection. Blood samples were collected for hepatic function analysis, and the living conditions and survival time were recorded. Liver injury was histologically analyzed. Hepatic cell regeneration and apoptosis were studied by Ki67 immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling, respectively. The levels of protein kinase B and nuclear factor-κB expression were analyzed by Western blotting.

Results: MSCs were infected with a lentivirus for expression of green fluorescent protein (GFP) for subsequent identification; 97.3% of the MSCs were positive for GFP as assessed by flow cytometry. Additional flow cytometric analysis of cell surface marker expression demonstrated that > 90% of GFP-expressing MSCs were also positive for CD29, CD44, and CD90, indicating that most of these cells expressed typical markers of MSCs, and the population of MSCs was almost pure. Transplantation of MSCs in combination with 2 mg/kg IL-1Ra therapy significantly improved survival time compared to the acute liver failure model group (35.3 ± 6.7 d vs 17.3 ± 5.5 d, P < 0.05). Combined therapy also promoted improvement in serum inflammatory cytokines and biochemical conditions. The observed hepatic histopathologic score was significantly lower in the group with combined therapy than in the model group (3.50 ± 0.87 vs 8.17 ± 1.26, P < 0.01). In addition, liver cell apoptosis in the combined therapy group was significantly inhibited (18.1 ± 2.1% vs 70.8 ± 3.7%, P < 0.01), and hepatic cell regeneration increased. A significant increase in protein kinase B expression and decrease in nuclear factor-κB expression were observed (P < 0.01), which supports their important roles in liver regeneration.

Conclusion: MSCs and IL-1Ra had a synergistic effect in liver regeneration via regulation of inflammation and apoptotic signaling.

Keywords: Acute liver failure; Hepatoectomy; Interleukin-1 receptor antagonist; Mesenchymal stem cells; Stem cell transplantation.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cytokines / blood
  • Disease Models, Animal
  • Hepatectomy*
  • Inflammation Mediators / blood
  • Interleukin 1 Receptor Antagonist Protein / pharmacology*
  • Ki-67 Antigen / metabolism
  • Liver / diagnostic imaging
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / surgery
  • Liver Failure, Acute / blood
  • Liver Failure, Acute / diagnosis
  • Liver Failure, Acute / pathology
  • Liver Failure, Acute / therapy*
  • Liver Function Tests
  • Liver Regeneration / drug effects*
  • Mesenchymal Stem Cell Transplantation*
  • NF-kappa B / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects
  • Swine
  • Swine, Miniature
  • Time Factors
  • Tomography, X-Ray Computed
  • Ultrasonography

Substances

  • Cytokines
  • Inflammation Mediators
  • Interleukin 1 Receptor Antagonist Protein
  • Ki-67 Antigen
  • NF-kappa B
  • Proto-Oncogene Proteins c-akt